Global, regional and country-level 90-90-90 estimates for 2018: assessing progress towards the 2020 target.


Journal

AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219

Informations de publication

Date de publication:
15 12 2019
Historique:
pubmed: 7 9 2019
medline: 2 10 2020
entrez: 7 9 2019
Statut: ppublish

Résumé

In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) and partners set the 90-90-90 target for the year 2020: diagnose 90% of all people living with HIV (PLHIV); treat 90% of people who know their status; and suppress the virus in 90% of people on treatment. In 2015, countries began reporting to UNAIDS on progress against 90-90-90 using standard definitions and methods. We used data submitted to UNAIDS from 170 countries to assess country-specific progress towards 90-90-90 through 2018. To assess global and regional progress, overall and by sex for adults aged 15 years and older, we combined country-reported data with estimates generated with a Bayesian hierarchical model. A total of 60 countries reported on all three 90s in 2018, up from 23 in 2015. Among all PLHIV worldwide, 79% (67-92%) knew their HIV status. Of these, 78% (69-82%) were accessing treatment and 86% (72-92%) of people accessing treatment had suppressed viral loads. Of the 37.9 million (32.7-44.0 million) PLHIV worldwide, 53% (43-63%) had suppressed viral loads. The gap to fully achieving 73% of PLHIV with suppressed viral load was 7.7 million; 15 countries had already achieved this target by 2018. Increased data availability has led to improved measures of country and global progress towards the 90-90-90 target. Although gains in access to testing and treatment continue, many countries and regions are unlikely to reach the 90-90-90 target by 2020.

Sections du résumé

BACKGROUND
In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) and partners set the 90-90-90 target for the year 2020: diagnose 90% of all people living with HIV (PLHIV); treat 90% of people who know their status; and suppress the virus in 90% of people on treatment. In 2015, countries began reporting to UNAIDS on progress against 90-90-90 using standard definitions and methods.
METHODS
We used data submitted to UNAIDS from 170 countries to assess country-specific progress towards 90-90-90 through 2018. To assess global and regional progress, overall and by sex for adults aged 15 years and older, we combined country-reported data with estimates generated with a Bayesian hierarchical model.
RESULTS
A total of 60 countries reported on all three 90s in 2018, up from 23 in 2015. Among all PLHIV worldwide, 79% (67-92%) knew their HIV status. Of these, 78% (69-82%) were accessing treatment and 86% (72-92%) of people accessing treatment had suppressed viral loads. Of the 37.9 million (32.7-44.0 million) PLHIV worldwide, 53% (43-63%) had suppressed viral loads. The gap to fully achieving 73% of PLHIV with suppressed viral load was 7.7 million; 15 countries had already achieved this target by 2018.
CONCLUSION
Increased data availability has led to improved measures of country and global progress towards the 90-90-90 target. Although gains in access to testing and treatment continue, many countries and regions are unlikely to reach the 90-90-90 target by 2020.

Identifiants

pubmed: 31490781
doi: 10.1097/QAD.0000000000002355
pmc: PMC6919229
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

S213-S226

Subventions

Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom

Références

AIDS. 2009 Jul 17;23(11):1397-404
pubmed: 19381076
AIDS. 2019 Feb 1;33(2):349-352
pubmed: 30557162
AIDS Rev. 2018 Apr-Jun;20(2):83-93
pubmed: 29938702
Lancet HIV. 2016 May;3(5):e221-30
pubmed: 27126489
Lancet HIV. 2018 Aug;5(8):e417-e426
pubmed: 30030134
PLoS Med. 2017 Apr 4;14(4):e1002253
pubmed: 28376085
Oman Med J. 2019 Jan;34(1):1-8
pubmed: 30671177
AIDS Behav. 2018 Aug;22(8):2435-2457
pubmed: 29464430
N Engl J Med. 2019 Jul 18;381(3):219-229
pubmed: 31314966
AIDS Res Ther. 2016 Sep 08;13(1):30
pubmed: 27617024
JMIR Public Health Surveill. 2017 Feb 03;3(1):e8
pubmed: 28159730
BMC Public Health. 2018 Mar 2;18(1):303
pubmed: 29499668
Curr Opin HIV AIDS. 2016 Mar;11 Suppl 1:S1-5
pubmed: 26945141
Curr Opin HIV AIDS. 2012 Mar;7(2):99-105
pubmed: 22227585
Science. 2013 Feb 22;339(6122):966-71
pubmed: 23430656
AIDS Behav. 2018 Mar;22(3):791-799
pubmed: 27990579
JMIR Public Health Surveill. 2018 May 22;4(2):e28
pubmed: 29789279
PLoS Med. 2017 Dec 12;14(12):e1002468
pubmed: 29232366
N Engl J Med. 2019 Jul 18;381(3):207-218
pubmed: 31314965
J Acquir Immune Defic Syndr. 2011 Aug;57 Suppl 2:S61-3
pubmed: 21857297
BMJ Glob Health. 2016 Sep 15;1(2):e000010
pubmed: 28588933
J Int Assoc Provid AIDS Care. 2017 Jan/Feb;16(1):75-80
pubmed: 26518590
AIDS. 2019 Dec 15;33 Suppl 3:S227-S234
pubmed: 31805028
AIDS. 2013 Apr 24;27(7):1159-65
pubmed: 23902921
AIDS. 2019 Dec 15;33 Suppl 3:S203-S211
pubmed: 31343430
PLoS One. 2016 May 09;11(5):e0154893
pubmed: 27159260
Lancet Infect Dis. 2014 Apr;14(4):281-90
pubmed: 24602844
PLoS One. 2018 Sep 19;13(9):e0201352
pubmed: 30231030
AIDS. 2019 Dec 15;33 Suppl 3:S255-S269
pubmed: 31764066
Clin Infect Dis. 2018 May 2;66(10):1487-1491
pubmed: 29324994
N Engl J Med. 2000 Mar 30;342(13):921-9
pubmed: 10738050
J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):28-37
pubmed: 29847474
J Community Health. 2018 Apr;43(2):338-347
pubmed: 28924725
Implement Sci. 2018 May 23;13(1):70
pubmed: 29792230

Auteurs

Kimberly Marsh (K)

aStrategic Information Department, The Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland bDepartment of Infectious Disease Epidemiology, Imperial College London, St Mary's Hospital, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH